Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ODYSSEY OPTIONS II: Alirocumab vs Ezetimibe or Rosuvastatin Dose Increase
NCT01730053Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2012
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of alirocumab in hypercholesterolemia (6 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent Change From Baseline in Calculated Low-Density Lipoprotein Cholesterol at 24 weeks. Started Nov 2012; status: completed.
02
Drugs
alirocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT01730053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01730053.